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Cancers promote immunological stresses that induce altera-tions of the myelopoietic output, defined as emergency myelopoiesis1–3, which lead to the generation of different 
myeloid populations endowed with tumor-promoting activities4. 
Among these, TAMs represent the final commitment of protumoral 
reprogramming of the myeloid lineage. TAMs promote tumor 
development by favoring angiogenesis, immunosuppression, tissue 
remodeling and metastasis formation5,6. These functions are coop-
eratively fulfilled by heterogeneous macrophage subsets stemming 
from a multistep process encompassing altered myelopoiesis, intra-
tumoral recruitment of TAM progenitors and their functional diver-
sion in response to microenvironmental signals7. Emerging evidence 
indicates that tumor-derived signals can actively reprogram macro-
phage metabolism8 and that distinct metabolic traits discriminate 
different macrophage differentiation and activation programs9. In 
this setting, while selected transcription factors such as cEBP! and 
ROR" (Rorc) regulate emergency myelopoiesis and contribute to 
the heterogeneous expansion of suppressive myeloid populations4, 
nuclear factor-#B1 (NF-#B1, also known as p50) stimulates neutro-
phil production by induction of c/EBP$10 and promotes resolution 
of inflammation by diversion of monocytes/macrophages toward 
a resolving anti-inflammatory M2-like phenotype11–13. However, 
even though the resolution phase of acute inflammatory response is 
crucial for tissue homeostasis and is supported by an adaptation of 
hematopoietic output to inflammatory insults, no information is yet 
available on the mechanisms linking altered myelopoiesis to macro-
phage shift toward an alternative M2-polarized state, as observed in 
persistent infections and cancer11–13.
Based on this premise, we investigated the heterogeneity of 
emerging myeloid populations in response to cancer-related inflam-
mation and observed that cancer growth promotes systemic expan-
sion of a myeloid subset endowed with high heme metabolism14. 
The expansion of both circulating HO-1+ monocytes and HO-1hi 
TAMs is associated with poor prognosis in both preclinal tumor 
models and patients with melanoma, and is dependent on the tar-
getable molecular axis p50 NF-#B–CSF-R1–C3aR–Nrf2–HO-1 that 
controls their differentiation, expansion and recruitment at the 
tumor site.
Results
p50 NF-!B controls the prometastatic activity of a distinct TAM 
subset. Given the overlapping traits between lipopolysaccharide 
(LPS)-tolerant macrophages and TAMs, which include nuclear 
accumulation of p50 NF-#B and M2-related features11–13, and based 
on the observation that acute stimulation of monocytes/macro-
phages with classic M1 polarization signals (for example, LPS) 
reduces their chemotactic reactivity to CC chemokines15, we first 
compared the chemotactic responsiveness of wild-type (WT) and 
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p50–/– peritoneal-elicited macrophages (PECs) in response to the 
anaphylatoxins C3a and C5a16. While both genetic backgrounds 
of macrophages expressed the chemotactic complement receptors 
C3aR and C5aR1 (also known as CD88) to a similar extent (Extended 
Data Fig. 1a), p50–/– PECs poorly migrated in response to C5a and 
C3a in vitro and showed impaired extracellular signal-regulated 
kinase (ERK)1/2 phosphorylation17 (Extended Data Fig. 1b–d). 
Moreover, unlike LPS-activated PECs (M/L), LPS-tolerant PECs 
(L/L) recovered their chemotactic responsiveness and ERK1/2 


















































































































































































































































































































































































































































































































































































































































































































Fig. 1 | Identification of two distinct F4/80hi and F4/80lo TAM subsets in primary and metastatic tumor lesions. a, Representative fluorescent activated 
cell sorter (FACS) plot of F4/80hi and F4/80lo TAMs in primary and metastatic MN/MCA1 tumors, in WT and p50%/% mice. n!=!5 (tumor) and n!=!7 
(metastasis) animals per genotype. b,c, Expression levels of myeloid markers and chemotactic receptors in F4/80hi (top) and F4/80lo (bottom) TAMs.  
b, n!=!6 (CD11b, MHCII, Ly6C, CD64, CX3CR1, CCR2), n!=!5 (CD11c F4/80hi) and n!=!4 (CD11c F4/80lo, CD206) mice. c, n!=!6 (C5aR1), n!=!4 (Tie2, C3aR) 
and n!=!3 (CCR5, CD115) mice. d, Boyden chamber migration assay of F4/80hi and F4/80lo TAMs, FACS sorted from WT sarcoma in comparison with PECs. 
n!=!6 animals per group. e, Representative FACS plot and frequency of F4/80hi and F4/80lo TAMs in primary lung tumors and metastases of p50fl/fl and 
p50fl/flLyz2-Cre MN/MCA1-bearing mice. n!=!7 (tumor) and n!=!5 (metastasis) mice per genotype. f, Representative FACS plot and frequency of F4/80hi and 
F4/80lo TAMs in primary tumors of p50fl/fl and p50fl/flLyz2-Cre B16-bearing mice. n!=!6 mice per genotype. a,e, Data are representative of five independent 
experiments. f, Representative experiment from n!=!2 performed. b–d, Data shown are pooled from n!=!2 independent experiments. a–f, Data are expressed 
as mean!±!s.e.m. *P!<!0.05, **P!<!0.01, ***P!<!0.001, ****P!<!0.0001 between selected relevant comparisons. Two-way analysis of variance (ANOVA) with 
"idák’s multiple comparisons test.
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manner (Extended Data Fig. 1g), indicating that p50 accumulation 
in tolerant macrophages restores ERK1/2 signaling.
Next, we sought to determine the role of p50 in TAM recruit-
ment in vivo. While implantation of the fibrosarcoma MN/MCA1 
in WT mice gave rise to readily identifiable F4/80lo and F4/80hi 
TAMs, we observed a selective reduction of the F4/80hi subset in 
p50–/– mice (Fig. 1a). Both subsets expressed the myeloid markers 
Ly6C, CD11c and CD11b and the chemokine receptors CX3CR1 
and CCR2, but they were negative for the granulocytic marker 
Ly6G (Fig. 1b). Importantly, in comparison with F4/80lo TAMs, 
F4/80hi TAMs expressed higher levels of MHCII, CD64, CD206 
(Fig. 1b), CCR5, the angiopoietin receptor Tie2 (Fig. 1c)—typi-
cally expressed by a proangiogenic monomacrophage subset18, the 
complement receptors C3aR and C5aR1 (CD88) and the macro-
phage colony-stimulating factor (M-CSF) receptor (also known as 
CSF1R, CD115), these last governing, respectively, recruitment and 
activation pathways (C3a and C5a)16 and differentiation and che-
moattraction (M-CSF)19 of myelomonocytic cells. The increased 
migration of F4/80hi TAMs to C5a, C3a and M-CSF (Fig. 1d) was 
confirmed in vivo by their higher intratumoral accumulation in 
both MN/MCA1 fibrosarcoma (primary and lung metastasis) (Fig. 
1e) and melanoma (B16F10) (Fig. 1f), which reduced following 
myeloid-specific ablation of p50 NF-#B (p50fl/flLyz2-cre mice).
Coinjection of F4/80hi-sorted TAMs and MN/MCA1 cells 
increased metastasis formation (Fig. 2a, bottom), expression of the 
endothelial marker CD31+ and tumor vessel length (Fig. 2b) without 
affecting primary tumor growth (Fig. 2a, top). In contrast, coinjec-
tion of F4/80lo TAMs reduced primary tumor growth (Fig. 2a, top) 
and vessel length (Fig. 2b) without affecting metastasis formation 
(Fig. 2a, bottom). Lastly, adoptive transfer of F4/80hi TAMs in p50–
/– mice20 restored tumor growth and lung dissemination (Fig. 2c), 
indicating that F4/80hi TAMs are both proangiogenic and prometa-
static. These results demonstrate that p50 NF-#B finely modulates 
the chemotactic responses of macrophages, favoring the accumula-
tion of a F4/80hi TAM population in the tumor lesion.
M-CSF and C3 promote accumulation of protumoral F4/80hi 
TAMs. We next investigated the accumulation pathways of TAMs 
in vivo by interference with M-CSF receptor (CSF1R) signaling19. 
Anti-CSF1R treatment of MN/MCA1-bearing mice markedly 
reduced F4/80hiCD115hi TAMs in primary and metastatic lesions 
(Fig. 3a), tumor growth (Fig. 3b) and metastasis formation (Extended 
Data Fig. 2a), number of intratumoral CD31+ endothelial cells 
and microvasculature density (Fig. 3c), number of intrametastatic 
CD31+ endothelial cells (Extended Data Fig. 2b) and F4/80hi TAM 
proliferation (Fig. 3d). The effects of anti-CSF1R treatment were 
further validated in the B16 melanoma model (Fig. 3e,f). Similarly, 
F4/80hi TAMs were reduced in both primary and metastatic lesions 
of C3–/– MN/MCA1-bearing mice, a phenomenon accompanied by 
decreased tumor growth, metastasis formation, number of CD31+ 
endothelial cells and vessel length (Fig. 3g–i and Extended Data Fig. 
2c,d. These results were reproduced in B16-bearing mice (Fig. 3j,k), 
supporting the tumor-promoting role of complement factors21,22.
In an effort to correlate the phenotypes of metastasis formation 
with abnormalities of tumor vasculature, vessel leakage, pericyte 
coverage and collagen IV (COL IV), a major constituent of the vas-
cular basement membrane, were evaluated in different genotypes. 
As ascertained by colocalization of intravenously injected 40-kDa 
dextran-fluorescein isothiocyanate (FITC) and CD31+ vessels, or 
CD31+ with either COL IV or $-SMA, tumors of C3–/– mice showed 
augmented vessel leakiness and diminished vessel coverage com-
pared to WT (Extended Data Fig. 2e). In contrast, anti-CSF1R treat-
ment did not affect vessel leakage while decreasing vessel coverage 
(Extended Data Fig. 2e). Thus, M-CSF and C3 combine to drive the 
accumulation of CD115hiC3aRhiF4/80hi TAMs, increasing tumor 
growth, angiogenesis and metastasis formation.
F4/80hi TAMs express high levels of HO-1 at the invasive tumor 
margin. To obtain deeper insights into the biology of TAMs, we next 
performed genome-wide analysis of TAM subsets. Principal com-










































































































































Fig. 2 | Distinct effects of F4/80hi and F4/80lo TAMs on metastasis formation and tumor angiogenesis. a, Tumor growth (top) and lung metastasis 
(bottom) in WT MN/MCA1 tumor-bearing mice adoptively transferred with F4/80hi or F4/80lo TAMs. n!=!6 (WT, WT!+!F4/80hi) and n!=!5 (WT!+!F4/80lo) 
mice. b, Immunofluorescence analysis, vessel length and relative quantification of CD31+ cells in MN/MCA1 tumors. n!=!6 (WT, WT!+!F4/80hi) and n!=!4 
(WT!+!F4/80lo) mice. Five random fields per sample were counted. c, Tumor growth (top) and number of lung metastases (bottom) in p50–/– MN/MCA1 
tumor-bearing mice adoptively transferred with WT F4/80hi TAMs. n!=!7 mice per group. Representative images are shown. Scale bars, 10!&m. a–c, Data 
are representative of two independent experiments and are expressed as mean!±!s.e.m. *P!<!0.05, **P!<!0.01, ***P!<!0.001, ****P!<!0.0001 between selected 
relevant comparisons. a,c, Two-way ANOVA with "idák’s multiple comparisons test and one-way ANOVA. b, One-way ANOVA and Kruskal–Wallis test with 
Dunn’s multiple comparisons test. NS, not significant.























































































































































































































































































































































































































































































































































































Fig. 3 | Pathways of F4/80hi TAM accumulation and contribution to tumor development. a, Frequency of F4/80hi and F4/80lo TAMs in vehicle- or 
anti-CSF1R-treated tumor-bearing mice. n!=!5 (vehicle) and n!=!4 (anti-CSF1R) mice. b, Tumor growth in WT MN/MCA1-bearing mice treated with vehicle 
or anti-CSF1R. c, FACS quantification (left), vessel length (center) and immunohistochemical analysis of CD31+ cells (right). Representative images are 
shown; 30!random fields per sample were counted. Scale bars, 10!&m. n!=!7 (vehicle) and n!=!5 (anti-CSF1R) mice. d, TAM proliferation in primary tumors 
from anti-CSF1R-treated mice. n!=!5 (vehicle) and n!=!4 (anti-CSF1R) mice. e, FACS plot and frequency of TAM subsets in vehicle- or anti-CSF1R-treated 
B16-bearing mice. n!=!5 mice per group. f, B16 tumor growth, percentage of CD31+ endothelial cells and proliferation rates of TAM subsets in WT mice 
treated with vehicle or anti-CSF1R. Left and center, n!=!6 mice per group; right, n!=!5 (vehicle) and n!=!4 (anti-CSF1R) mice. g, Representative dot plot and 
frequency of F4/80hi and F4/80lo TAM subsets in WT or C3–/– MN/MCA1-bearing mice. Tumor, n!=!5; metastasis, n!=!5 (WT) and n!=!4 (C3–/–) mice.  
h, Tumor growth in WT or C3–/– MN/MCA1-bearing mice. n!=!7 mice per genotype. i, FACS quantification (top) and immunofluorescence analysis of CD31+ 
cells and vessel length (bottom). Representative images are shown; 30!random fields per sample were counted. Scale bars, 10!&m. n!=!5 mice per genotype. 
j, Representative dot plot and frequency of F4/80hi and F4/80lo TAM subsets in WT and C3–/– B16-bearing mice. n!=!6 mice per genotype. k, Tumor growth 
of B16 melanoma in WT and C3–/– mice (left); FACS quantification of CD31+ cells (right). n!=!5 mice per genotype. a,b, Data are representative of three 
independent experiments. c (left),d,g,h, Data are representative of two independent experiments. c (right),e,f,i–k, One experiment was performed. Data 
are mean!±!s.e.m. *P!<!0.05, **P!<!0.01, ***P!<!0.001, ****P!<!0.0001 between selected relevant comparisons. a,b,d,e–h, Two-way ANOVA with "idák’s 
multiple comparisons test. c,f,j,k, Two-tailed unpaired Student’s t-test or Mann–Whitney U-test.
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transcriptional landscape of F4/80hi and F4/80lo TAMs (Fig. 4a,b). 
Pairwise differential analysis between F4/80hi and F4/80lo TAMs and 
PECs identified a set of 5,587 differentially modulated genes (Fig. 4b 
and Supplementary Table 1), including the markers of poor progno-
sis in breast cancer SIGLEC1 and CCL8 (ref. 23). Specifically, gene 
ontology (GO) enrichment analysis showed remarkable differences 
in iron metabolism as demonstrated by differential expression of 
iron-regulated genes (Fig. 4c,d). Since the vast majority of iron is 
contained within the protoporphyrin ring of heme24 and, given that 
HO-1-driven heme catabolism exerts potent antioxidant, cytopro-
tective and immunoregulatory activities14,25 in various tumors26, we 
measured gene expression levels of the alternative activation marker 
HO-1 (Hmox1)27. F4/80hi TAMs expressed higher levels of Hmox1 
messenger RNA and protein (Fig. 4e, left).
Based on this evidence, TAMs were analyzed for mRNA levels of 
genes involved in both heme biosynthesis (Alas1, Alad, Urod, Cpox, 
Fech, Ppox, Hmbs)28 and endocytic supply (CD163, a regulated 
hemoglobin scavenger receptor with a role in the anti-inflammatory 
response). Although the two populations of TAMs did not show 
significant differences in expression levels of heme biosynthetic 
genes (Alas1, Alad, Urod, Cpox, Fech, Ppox, Hmbs) (not shown), 
F4/80hiHO-1hi TAMs displayed increased CD163 expression (Fig. 
4e, right), indicating CD163-mediated haptoglobin-hemoglobin 
endocytosis as their primary route of heme feeding.
We next determined the topographical localization of HO-1+ 
TAMs as a potential indicator of prognosis2. Confocal micros-
copy and immunohistochemical analysis of MN/MCA1 tumors 
showed HO-1% TAMs to be preferentially localized in inner tumor 
areas whereas HO-1+ TAMs accumulated at their invasive margin 
(Extended Data Fig. 3a), consistent with neoangiogenesis and can-
cer cell spread29. This observation was confirmed in human meta-
static melanoma lesions where CD68+ TAMs, coexpressing the 
alternative M2 activation markers HO-1 and CD163 (ref. 3), accu-
mulated preferentially at the invasive tumor edge (Extended Data 
Fig. 3b). Therefore, the invasive margin of primary and metastatic 
tumors is the preferred site of accumulation of a distinct population 
of macrophages endowed with high heme metabolism.
Myeloid-specific heme catabolism orchestrates metastasis for-
mation. To determine whether HO-1 expression by F4/80hi TAMs 
contributes to tumor development, we used Hmox1fl/flLyz2-Cre mice 
in which Hmox1 is specifically deleted in the myeloid compartment. 
While ablation of HO-1 did not affect primary MN/MCA1 tumor 
growth (Fig. 5a, left), it reduced lung metastasis formation (Fig. 
5a, right and Extended Data Fig. 3c), frequency of F4/80hi TAMs 
(Fig. 5b, left) and CD31+ endothelial cell numbers in both primary 
and metastatic lung tumors (Fig. 5c and Extended Data Fig. 3d). 
Of note, the reduced number of F4/80hi TAMs observed under 
HO-1-deficient conditions was paralleled by the reduced surface 
expression of both M-CSF receptor (CD115) and cell proliferation 
(Fig. 5b, right).
Similarly with C3–/– mice, as compared to Hmox1fl/fl mice, an aug-
mented vascular leakage was observed in Hmox1fl/flLyz2-Cre mice 
(Extended Data Fig. 3e top) that was accompanied by decreased 
colocalization of CD31+ and COL IV (Extended Data Fig. 3e, bot-
tom left). However, no differences were observed in colocaliza-
tion between CD31+ and $-SMA (Extended Data Fig. 3e, bottom 
right), indicating higher vessel density as the prominent prometa-
static determinant. In agreement, evaluation of expression lev-
els of angiogenic molecules in CD31+ cells and TAMs (Extended 
Data Fig. 3f) showed higher levels of hypoxia-inducible factor 1$ 
(HIF1$), vascular endothelial growth factor (VEGF) and VEGF 
receptor (VEGFR) in both primary tumor (top) and lung metas-
tasis (bottom) of Hmox1fl/fl tumor bearing mice, as compared to 
Hmox1fl/flLyz2-Cre mice. Furthermore, HO-1 deletion promoted an 
M2 (TNFloCD206hip-STAT1lop-STAT3hip-STAT6hi) to M1 (TNF$hiC
D206lop-STAT1hip-STAT3lop-STAT6lo) phenotypic switch of F4/80hi 
TAMs3,13 (Fig. 5d) and reactivated the specific immune response, 
as shown by increased IFN" and GrzB expression in CD8+ T cells, 
a higher frequency of effector memory CD8+CD44+CD62L– cells 
and an augmented CD8+/CD4+FoxP3+ (regulatory T cell (Treg)) 
ratio (Fig. 5e).
To further investigate the role of HO-1 in metastasis, we first 
evaluated the number of circulating tumor cells in myeloid-specific 
proficient and deficient conditions since their presence correlates 
with poor clinical outcome in several cancers. In agreement with 
Extended Data Fig. 3c, quantification of circulating MN/MCA1 
mCherry+ tumor cells, either by cytofluorimetry or PCR with reverse 
transcription (RT–PCR) for mCherry gene expression (Fig. 5f), 
confirmed their reduced levels under HO-1-deficient conditions. 
In agreement, Hmox1/HO-1 deletion correlated with inhibition of 
tumor cell epithelial-to-mesenchymal transition (EMT), as shown 
by decreased expression of mesenchymal markers Cdh2 (encod-
ing N-cadherin), Twist (encoding the Twist-related protein 1), Vim 
(encoding vimentin) and Snai1 (encoding Snail) and enhanced 
expression of E-cadherin and Epcam (respectively encoding the epi-
thelial marker E-cadherin and the epithelial cellular adhesion mol-
ecule also known as CD36) (Extended Data Fig. 4a). Inhibition of 
primary and metastatic tumors following myeloid-specific Hmox1 
deletion was confirmed in the B16 melanoma model (Extended 
Data Fig. 4b) and was paralleled by an M2 (TNFlo, CD206hi) to 
M1 (TNFhi, CD206lo) phenotypic switch of TAMs and lower 
frequency of CD31+ cells (Extended Data Fig. 4c), increased 
number of tumor-infiltrating IFN-"+CD8+ T cells, enhanced 
CD8+/Treg cell ratio (Extended Data Fig. 4d) and reduced EMT 
(Extended Data Fig. 4e).
Since the cytoprotective effect of HO-1 is exerted essentially 
via the catabolism of cytotoxic labile heme30 and the generation 
of carbon monoxide (CO)14, which acts in a noncell-autonomous 
manner, we asked whether HO-1+ TAM-mediated production of 
CO would favor tumor growth. To determine how heme catabo-
lism by HO-1 modulates macrophage activation, we treated M/L 
or L/L PECs with the HO-1 enzymatic inhibitor zinc protoporphy-
rin IX (ZnPPIX)31. Inhibition of HO-1 enzymatic activity restored 
expression of the prototypical M1 genes TNF and CXCL10 by L/L, 
while it downregulated gene expression of M2, IL-10 and CCL22 
(ref. 13) (Extended Data Fig. 4f). Consistent with the observation 
that deletion of NF-#B1 leads to both aberrant expression of the 
proinflammatory cytokines TNF and CXCL10 and reduced expres-
sion of the anti-inflammatory M2 mediators IL-10 and CCL22 
(ref. 13), the CO-releasing molecule CORM-2 reversed the effects 
caused by NF-#B1 deletion or inhibition of HO-1 activity (Extended 
Data Fig. 4g,h). These data indicate that high HO-1 expression in 
TAMs supports metastasis formation by promotion of tumor angio-
genesis, M2 polarization of macrophages, inhibition of CD8+ T cells 
and EMT transition.
CSF1R guides the expansion of HO-1-expressing myeloid cells. 
In agreement with NF-#B1 as a regulator of myeloid-specific HO-1+ 
myeloid populations under LPS-tolerant conditions (Extended Data 
Fig. 4i), expansion of Ly6Clow/%F4/80+SiglecF%C5aR1+C3aR+HO-1+ 
blood cells in fibrosarcoma-bearing mice (Fig. 6a) was prevented by 
p50 deletion (p50–/– mice) (Fig. 6g).
To better investigate the role of p50 NF-#B, CSF1R and C3aR 
in the generation of HO-1+ myeloid cells, we evaluated expres-
sion of the transcription factor Nrf2, a well-known inducer of 
HO-1-expressing hemophagocytic macrophages32. In line with the 
higher expression of HO-1, TAM F4/80hi expressed higher levels 
of Nrf2 (Extended Data Fig. 5a, left), which was reduced by both 
anti-CSF1R treatment and C3 depletion (C3–/– mice) (Extended 
Data Fig. 5a, middle). Further, estimation of HO-1 mean fluores-
cence intensity (MFI) showed reduced Nrf2 levels following either 
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Fig. 4 | Genomic analysis of HO-1+ TAMs. a, PCA of genes in PECs and F4/80lo and F4/80hi TAMs. Colors indicate group identity: white, PECs; gray, 
F4/80lo TAMs; red, F4/80hi TAMs (n!=!9). Averaged sample variance for each group is represented by large circles. Percentage of variance for each 
principal component (Dim1, Dim2) is indicated on the axes. b, Heatmap showing hierarchical clustering of 5,587!significantly differentially expressed genes 
among PECs and F4/80lo and F4/80hi samples. Adjusted P!'!0.05; false discovery rate correction for multiple testing. Scale bar representing expression 
z-score is shown on the right. Black dots on the left indicate whether a gene was found significantly differentially expressed in the pairwise comparison 
shown above. c, Bar plot showing representative GO gene set found significantly enriched (adjusted (adj.) P!'!0.1) among 5,587!significantly differentially 
expressed genes. The gene set was retrieved from the Molecular Signatures Database (c5.bp.v6.2). d, Heatmap showing hierarchical clustering of 
64!significantly differentially expressed genes belonging to the gene set categories shown in c. Scale bar representing expression z-score is shown on the 
right. Black dots on the left indicate whether a gene was present in the gene set categories shown above. e, mRNA levels of HO-1 in PECs and F4/80lo and 
F4/80hi TAMs (left); shown are pooled data from n!=!3 independent experiments with n!=!3 animals per group; representative FACS plot and quantification 
of HO-1 expression by F4/80hi and F4/80lo TAMs in MN/MCA1 tumors (middle). n!=!5 mice; data are representative of three independent experiments; 
representative FACS plot and quantification of CD163 expression by F4/80hi and F4/80lo TAMs in MN/MCA1 tumors (right). n!=!4 mice; data are 
representative of n!=!2 independent experiments. Data are mean!±!s.e.m. ***P!<!0.001, ****P!<!0.0001 between selected relevant comparisons. e, One-way 
ANOVA or two-tailed unpaired Student’s t-test.
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anti-CSF1R treatment, C3 depletion (C3–/– mice) or p50 NF-#B 
depletion (p50–/– mice) (Extended Data Fig. 5a, right), indicating 
their regulation of Hmox1 transcription.
Further, in accordance with the M-CSF-dependent expansion of 
F4/80hi TAMs, depletion of either p50 NF-#B or C3 decreased the 
expression levels of CSF1R (CD115) by these cells (Extended Data 
Fig. 5b). In agreement, in vitro treatment of PECs with C3 enhanced 
the expression of both Nrf2 and HO-1 in a p50 NF-#B-dependent 
manner (Extended Data Fig. 5c), indicating that additional cir-
cuits, independent of the C3–p50 axis, can support the levels of 
Nrf2 in vivo (Extended Data Fig. 5a, center), while M-CSF-induced 
expression of both Nrf2 and HO-1 was reduced by p50 and C3 abla-
tion (Extended Data Fig. 5d). The induction of C3aR and CD115 by 
their reciprocal ligands further supported their functional interplay 
(Extended Data Fig. 5c,d).
Corroborating this finding, in vitro treatment of WT BM-derived 
macrophages (BM-DMs) with either C3 or M-CSF enhanced the 
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Fig. 5 | Role of myeloid-specific HO-1 in cancer development. a, MN/MCA1 growth (left, n!=!7 mice per genotype) and lung metastases (right) in Hmox1fl/fl  
(n!=!15) mice and Hmox1fl/flLyz2-Cre (n!=!21) mice. b–e, Leukocyte infiltration in Hmox1fl/fl and Hmox1fl/flLyz2-Cre MN/MCA1-bearing mice. b, Frequency 
of TAM subsets, CD115 expression and proliferation rates of TAM subsets in Hmox1fl/fl and Hmox1fl/flLyz2-Cre MN/MCA1-bearing mice; n!=!6 mice per 
genotype. c, FACS and immunohistochemical analysis of CD31+ cells; n!=!5 mice per genotype. Representative images are shown, with 30!random fields 
per sample counted. Scale bars, 10!&m. d, Expression of TNF+ and CD206+ (top, n!=!5 mice per genotype) and pSTAT1, pSTAT3 and pSTAT6 (bottom, n!=!2 
mice (Hmox1fl/fl) and n!=!3 mice (Hmox1fl/flLyz2-Cre)) in TAM subsets. e, IFN-"+ and GrzB+ in CD8+ T!cells, effector memory (CD44+CD62L%) CD8+ T!cells 
and CD8+/Treg ratio; n!=!5–6 mice per genotype. f, Top and bottom left: representative FACS plot and quantification of circulating MN/MCA1 mCherry+ 
tumor cells in blood of Hmox1fl/fl and Hmox1fl/flLyz2-Cre MN/MCA1-bearing mice 20!days after injection of tumor cells; n!=!5 mice (Hmox1fl/fl) and n!=!7 mice 
(Hmox1fl/flLyz2-Cre). Bottom right: blood was collected from n!=!4 Hmox1fl/fl and n!=!4 Hmox1fl/flLyz2-Cre MN/MCA1-bearing mice 20!days after injection of 
tumor cells and analyzed by RT–PCR for mCherry expression. a (left),b, Data are representative of three independent experiments. a (right), Data from 
pooled (n!=!3) experiments. c,d (top), Data are representative of two independent experiments. d (bottom),f, One experiment was performed. Data are 
mean!±!s.e.m. *P!<!0.05, **P!<!0.01, ***P!<!0.001 between selected relevant comparisons. a–d, Two-way ANOVA with "idák’s multiple comparisons test. 
b,e,f, Two-tailed unpaired Student’s t-test or Mann–Whitney U-test.
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firm the role of Nrf2 in HO-1 induction, we next took advantage 
of Nrf2-deficient (Nfe2l2%/%) BM-DMs. Consistently, the induced 
expression of HO-1, by either C3 or M-CSF was reduced follow-
ing Nrf2 ablation (Extended Data Fig. 5e, right). Accordingly, 
in vivo treatment of fibrosarcoma-bearing WT mice with brusatol, 
a specific Nrf2 inhibitor33, reduced lung metastasis formation in 
WT mice while this effect was lost in either C3-, p50-, M-CSF- or 
myeloid-specific HO-1 depletion (Extended Data Fig. 5f). Moreover, 
while brusatol did not affect the frequency of F4/80hi TAMs, it 
reduced their expression of HO-1 only in WT mice (Extended Data 
Fig. 5g, top). This finding was consistently mirrored by the reduced 
frequency of HO-1-expressing granulocyte/monocyte progenitors 
(GMPs) within the lineage-negative and c-Kit-positive hematopoi-
etic cells (Lin–c-Kit+, LK) fraction in response to brusatol treatment 
(Extended Data Fig. 5g, bottom).
To track the ontogeny of HO-1+ myeloid cells, lethally irradiated 
CD45.2+ mice were adoptively transferred with BM cells derived 
from CD45.1+ mice and, 8 weeks later, injected with MN/MCA1 
cells. The vast majority (>90%) of immune cells in both primary 
tumors and blood were BM donor-derived (CD45.1), among which 
CD45.1+ TAMs displayed higher levels of HO-1 and CCR2 expres-
sion (Fig. 6b). We next sought to determine the commitment of 
Lin%Sca-1+ hematopoietic progenitors into common myeloid pro-
genitors (CMPs), GMPs or megakaryocyte/erythroid progenitors 
(MEPs). Whereas cancer growth increased the frequency of HO-1+ 
GMPs (Fig. 6c), anti-CSF1R treatment or NF-#B1 deletion reduced 
HO-1-expressing GMPs and Gr1%CD11b+F4/80+ BM cells within 
the LK fraction (Fig. 6d,e).
In contrast, C3 deletion did not impair the expansion of myeloid 
HO-1+ cells in the BM (Fig. 6d,e). Furthermore, the number of blood 
F4/80+CD88+C3aR+ cells expressing HO-1 was drastically reduced 
following treatment with anti-CSFR-1 or deletion of either NF-#B1 
or C3 (Fig. 6f,g), indicating that this distinct myeloid subset catabo-
lizes heme through HO-1 during emergency myelopoiesis instigated 
by pathological inflammation34. Consistently, anti-CSF1R treatment 
or NF-#B1 ablation in fibrosarcoma-bearing mice reduced levels 
of blood carboxyhemoglobin (COHb), a stable hemoglobin (Hb) 
complex acting as an indirect indicator of endogenous CO produc-
tion35 (Fig. 6h, left). In line with a systemic increase of COHb, tumor 
growth enhanced the expression of HO-1 also in spleen and liver 
macrophages (Fig. 6h right).
Furthermore, either condition conferred specific antitumor 
immunity to tumor lesions as evidenced by enhanced expres-
sion of IFN" and GrzB in CD8+ T cells, higher frequency of 
CD8+CD44+CD62L% effector memory cells and increased CD8+/
Treg (CD4+FoxP3+) cell ratio (Fig. 6i). When HO-1-proficient mice 
were subcutaneously injected with 5 ( 105 B16 cells and 3 days later 
treated with the HO-1 inhibitor ZnPPIX (Extended Data Fig. 6a–c), 
we observed reduced melanoma growth and reprogramming of 
myeloid and lymphoid functions, as also detected in B16-bearing 
Hmox1fl/flLyz2-Cre mice (Extended Data Fig. 4b–d). According, ex 
vivo treatment with ZnPPIX of FACS-sorted TAMs promoted a 
M2-to-M1 functional switch (Extended Data Fig. 6d). Analysis of 
HO-1 levels in TAMs and cancer cells, from both MN/MCA1 and 
B16 tumors, confirmed higher HO-1 levels in the F4/80hi TAM pop-
ulation (Extended Data Fig 6e). In agreement, the antitumor activ-
ity of ZnPPIX treatment was lost in Hmox1fl/flLyz2-Cre B16-bearing 
mice (Extended Data Fig 6f, left). Of relevance, no differences were 
observed in the proliferation rate of MN/MCA1 and B16 cancer cells 
in response to ZnPPIX treatment (Extended Data Fig. 6f, right). The 
antimetastatic activity of ZnPPIX was confirmed in the metastatic 
melanoma model K1735-M2 (Extended Data Fig. 6g).
In support of the key role of CO in the polarization of TAMs, 
CORM-2 treatment of FACS-sorted TAMs reduced phosphoryla-
tion of the transcription factor STAT1 involved in M1 activation 
of macrophages while upregulating the phosphorylation of the 
M2-related transcription factors STAT6 and STAT3 (Extended Data 
Fig. 6h, top)36. According, TAMs treated ex vivo with CORM-2 
upregulated the expression of typical M2-polarization markers (that 
is, CD206. CCL22, Arg1 and IL-10) and downregulated the expres-
sion of M1 markers (that is, TNF, CXCL10 and IL12p40) (Extended 
Data Fig. 6h, bottom).
Of note, depletion of CD4+ and CD8+ T lymphocytes in MN/
MCA1 tumor-bearing mice reduced the antimetastatic activity of 
Fig. 6 | Role of CSF1R in HO-1+ TAM differentiation. a, Frequency of F4/80+C3aR+C5aR+Ly6Clow/%SiglecF% blood monocytes (left) and relative HO-1 
expression (right) in WT naive and MN/MCA1 tumor-bearing mice. n!=!7 mice per group. b, Lethally irradiated CD45.2+ mice were grafted with syngeneic 
BM CD45.1+ cells and, after 8!weeks, injected with MN/MCA1 tumor cells. Left, level of chimerism (percentage of CD45.1+ and CD45.2+ cells) within blood 
and tumor-infiltrated leukocytes (percentage of CD45+ cells). Middle, HO-1 expression by CD45.2+ and CD45.1+ F4/80hi TAMs. Right, CCR2 expression 
in HO-1hi and HO-1lo/% F4/80hi TAMs. n!=!5 mice per group. c, Left, percentage of CMPs (CD16/32%CD34+ cells), MEPs (CD16/32%CD34% cells) and GMPs 
(CD16/32+CD34+ cells). Right, HO-1 expression in BM of WT naive and MN/MCA1 tumor-bearing mice. n!=!3 or 4 mice per group. d, Percentage of 
CMPs, MEPs and GMPs and relative HO-1 expression in BM of untreated and anti-CSF1R-treated melanoma-bearing WT mice (top) and of WT, p50–/– and 
C3–/– fibrosarcoma-bearing mice (bottom). n!=!4–6 mice per group. e, Percentage of Gr1%CD11b+F4/80+ cells (left, second from right) and relative HO-1 
expression (right, second from left) in BM of untreated and anti-CSF1R-treated melanoma-bearing WT mice (left, second from left) and of WT, p50–/– and 
C3–/– fibrosarcoma-bearing mice (right, second from right). Right, n!=!4 or 8 (WT) and n!=!4–5 (p50–/– and C3–/–) mice. Left, n!=!4 (tumor-free), n!=!10 
(vehicle) and n!=!6 (anti-CSF1R) mice. f, F4/80+C3aR+C5aR+Ly6Clow/%SiglecF% monocyte frequency (left) and relative HO-1 expression (right) in blood 
of untreated and anti-CSF1R-treated B16-bearing WT mice. n!=!5–6 mice per group. g, Frequency of F4/80+C3aR+C5aR+Ly6Clow/%SiglecF% monocytes 
(left, second from right) and relative HO-1 expression (right, second from left) in blood of untreated and anti-CSF1R-treated fibrosarcoma-bearing WT 
and p50–/– fibrosarcoma-bearing mice and of WT and C3–/– sarcoma-bearing mice. Left, n!=!2 (tumor-free), n!=!4–5 (vehicle and anti-CSF1R) mice. Right, 
n!=!4–5 mice per group. h, Effects of anti-CSF1R on blood levels of COHb in WT and p50–/– MN/MCA1-bearing mice (left) and of HO-1 in splenic and liver 
macrophages in tumor-free and tumor-bearing WT mice (right). Left, n!=!5 (WT) and n!=!6 (p50–/–) mice. Right, n!=!4–5 mice per group. i, IFN-"+ and GrzB+ 
in CD8+ T and effector memory CD8+ T!cells and the CD8+/Treg ratio in WT and p50–/– MN/MCA1-bearing mice, treated or not with anti-CSF1R. n!=!4 mice 
per group. j, Tumor volume and lung metastatic area in T-lymphocyte-depleted (anti-CD4/CD8) MN/MCA1-bearing WT mice, treated or not with ZnPPIX 
(HO-1 antagonist); the area of metastatic burden was quantified from H&E-stained lung sections from the same sample and is expressed as a percentage 
of total lung surface area. Representative images are shown. Scale bars, 1!mm. Left, n!=!5 (vehicle and ZnPPIX) and n!=!6 (anti-CD4/CD8!+!ZnPPIX) mice. 
Right, n!=!3 (vehicle and ZnPPIX) and n!=!6 (anti-CD4/CD8!+!ZnPPIX) mice. k, MN/MCA1 growth and metastatic area in Hmox1fl/fl and Hmox1fl/flLyz2-Cre 
mice, treated or not with anti-PD-1 antibody; the area of metastatic burden was quantified from H&E-stained lung sections from the same sample and is 
expressed as a percentage of total lung surface area. Representative images are shown. Scale bars, 1!mm. n!=!8 (Hmox1fl/fl vehicle, Hmox1fl/fl!+!anti-PD-1) and 
n!=!7 (Hmox1fl/flLyz2-Cre vehicle and Hmox1fl/flLyz2-Cre!+!anti-PD-1) mice. a, Data are representative of two independent experiments. b–k, One experiment 
was performed. Data are mean!±!s.e.m. NS, not significant. *P!<!0.05, **P!<!0.01, ***P!<!0.001, ****P!<!0.0001 between selected relevant comparisons. a–g, 
One-way ANOVA or two-tailed unpaired Student’s t-test. h–j, Two-way ANOVA with "idák’s multiple comparisons test. k, One-way ANOVA followed by 
Tukey’s multiple comparison test.
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ZnPPIX (Fig. 6j), confirming the immunosuppressive effects of 
HO-1-driven heme catabolism. Further, while ZnPPIX treatment 
inhibited the frequency of CD31+ cells in primary tumors, as well 
as EMT activity, both events were reversed by CD4+/CD8+ T-cell 
depletion (Extended Data Fig. 6i). In good agreement with a protu-
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in MN/MCA1 fibrosarcoma (Fig. 6k) or ZnPPIX cotreatment of 
B16 melanoma (Extended Data Fig. 6j) improved the antitumor 
efficacy of an anti-PD-1 monoclonal antibody37. Thus, C3 and 
M-CSF activities converge on Nrf2 activation in a p50-dependent 
manner, promoting the expansion of BM-derived HO-1+  
TAMs that fuel CO-mediated M2 polarization and inhibit antitu-
mor immunity.
Prognostic significance of myeloid-specific HO-1 in melanoma 
patients. Since our results indicated that the accumulation of pro-
angiogenic and prometastatic HO-1+ TAMs is consistent with the 
increased number of HO-1+ blood monocytes observed in tumor 
bearers, we assessed the potential prognostic significance of HO-1 
expression in 15 blood monocyte subsets (R1–R3 and R1R5–R3R8) 
(Extended Data Fig. 7a) of two consecutive cohorts of patients 
with American Joint Committee on Cancer (AJCC) stage IIIC/
IV melanoma (discovery cohort: n = 47; confirmation cohort: 
n = 45) (Supplementary Table 2 and Extended Data Fig. 7b,c). 
Semiparametric Cox regression analyses revealed a significant asso-
ciation of HO-1 expression values (geometric mean of fluorescence 
intensity, gMFI) with survival in both patient cohorts (Fig. 7a–c, 
Extended Data Fig. 8a,b and Supplementary Table 3a,c).
To establish a clinical and phenotypic connection between 
peripheral blood and the tumor microenvironment, we first per-
formed immunohistochemistry on a panel of metastatic lesions 
from patients with stage III melanoma, to test for HO-1 expres-
sion. HO-1 staining was observed in the same stromal or intratu-
mor areas positive also for the M2 marker CD163 (Extended Data 
Fig. 9a, patient nos. 1–8). Lesions lacking HO-1 were also nega-
tive for CD163 (Extended Data Fig. 9a, patient nos. 11–15). In 
this small panel of lesions, HO-1 expression was observed in 
patients with shorter survival compared with HO-1-negative cases 
(Extended Data Fig. 9a). Moreover, by using the survival module 
of the TIMER2.0 web resource for analysis of immune infiltrates 
across diverse cancer types, we tested the potential prognostic 
significance of both HMOX1 gene expression and macrophage 
gene-signature M2_TIDE in The Cancer Genome Atlas (TCGA) 
melanoma dataset. In addition to clinical stage, both M2_TIDE 
gene signature and HMOX1 gene expression were significant in a 
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Fig. 7 | Prognostic significance of myeloid-specific HO-1. a, Gating strategy to identify three key blood monocyte subsets (R1–R3) in patients with 
melanoma. b, Expression of HO-1 (gMFI) in subsets R1–R3 from the discovery and confirmation sets of patients with AJCC stage!IIIC/IV melanoma.  
c, Kaplan–Meier survival analysis in discovery (left) and confirmation sets (right) stratified by monocyte subset-specific HO-1 gMFI median value of the 
combined set (discovery!+!confirmation). b,c, n!=!47 (discovery set) and n!=!45 (confirmation set) patients. Data are mean!±!s.e.m. NS, not significant. 
*P!<!0.05, ****P!<!0.0001 between selected relevant comparisons using Mann–Whitney U-test.
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macrophage-related genes (CD163 and CD68) were not. Together 
with our preclinical evidences, these results confirm that tumors 
induced expansion of blood monocytes and TAMs expressing 
HO-1, establishing correlation of their increased frequency with a 
negative prognosis.
Discussion
Tumors promote a pathological expansion of myeloid populations, 
whose specialized heterogeneity differentially affects disease pro-
gression34,38. Deciphering the molecular basis of such heterogeneity 
remains a great challenge that is expected to reveal therapeutic oppor-
tunities through restoration of anticancer functions. Our findings 
add to the complexity of TAM specialization39 by identifying the 
pathways involved in differentiation (M-CSF) and recruitment 
(M-CSF and C3a) of distinct BM-derived, prometastatic HO-1+ 
TAMs. We provide evidence that, in response to immunological 
stresses such as those promoted by bacterial products and grow-
ing tumors, a distinct HO-1-expressing monocyte/macrophage 
population emerges from BM precursors. Phenotypically, HO-1+ 
TAMs resemble the erythrophagocytic macrophages present in the 
red pulp of the spleen and, to some extent, those in the liver, which 
play a crucial role in iron metabolism and are specialized in heme 
biosynthesis originating from senescent red blood cells40. In can-
cer this population accumulates in blood and at the invasive tumor 
margin under the influence of the p50 NF-#B–CSF-R1–C3aR 
axis, which converges on Nrf2 activation to support HO-1 expres-
sion by TAMs.
This finding offers a new example of cooptation of physiologi-
cal functions used by tumors. Thus, while HO-1 catabolism has 
homeostatic properties offering protection against a variety of 
immune-mediated inflammatory diseases41, our findings indicate 
that tumors exploit HO-1 activity by myeloid cells to promote 
immunosuppression, angiogenesis and EMT, enhancing metasta-
sis formation. Importantly, HO-1+ TAMs appear to be a druggable 
target since pharmacological inhibition or myeloid-specific ablation 
of HO-1 prevented these protumor events while increasing specific 
antitumor immunity and the efficacy of anti-PD-1-mediated immu-
notherapy. In agreement, similar antitumor effects were obtained 
through inhibition of recruiting pathways of HO-1+ TAMs (that is, 
M-CSF or C3a). The clinical relevance of the HO-1+ myeloid popu-
lation was demonstrated both by immunohistochemical investiga-
tion of metastatic lesions from patients with stage III melanoma and 
by evaluation of the prognostic significance of the HMOX1 gene 
in the TCGA melanoma dataset. Furthermore, correlation of blood 
levels of HO-1+ myeloid cells in patients with stage III/IV melanoma 
correlated this population with a worse survival, identifying this 
population also as a prognostic blood marker. Interestingly, HO-1+ 
TAMs express high levels of SIGLEC1 and CCL8 genes, two mark-
ers of poor prognosis recently identified in a distinct TAM sub-
group found in patients with breast cancer23. Based on the crucial 
role of CO in protumoral TAM M2 polarization, and the possibility 
of modulation of blood COHb levels through HO-1+ myeloid cell 
depletion, our study also suggests a thorough review of the impact 
of cigarette smoking on prognosis and therapeutic response in can-
cer patients.
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Methods
Animals. All mice used in this study were 8–12 weeks of age, and both males and 
females were used. Individual experiments were age and sex matched. Wild-type 
C57BL6/J and C3H/HeN mice were obtained from Charles River Laboratories. 
NF-#B1/p50-de$cient mice were available in-house20. Homozygous C3 mutant 
mice (B6;129S4-C3tm1Crr/J) were purchased from Jackson Laboratories. NFKB1#ox/
#ox (p50#/#) mice were recently generated in our laboratory11. p50#/# mice were 
crossed with B6.129P2-Lyz2tm1(cre)Ifo/J mice (Jackson Laboratories) to generate 
p50#/!Lyz2-Cre mice. Hmox1#/# and Hmox1#/#Lyz2-Cre mice42 were kindly provided 
by B. Wegiel (Beth Israel Deaconess Medical Center, Harvard Medical School, 
Boston, USA). All colonies were housed and bred in the speci$c-pathogen-free 
animal facility at the Humanitas Clinical and Research Center (Rozzano, Milan, 
Italy) in individually ventilated cages. Mice were housed under a 12/12-h light/
dark cycle at an ambient temperature of 22 ± 1 °C with humidity 52–55%. Mice 
were randomized based on sex, age and weight. All procedures involving handling 
and care of C57BL/6J mice complied with protocols approved by the Humanitas 
Clinical and Research Center and in accordance with national (Legislative 
Decree no. 116, G.U., suppl. 40, 02-18-1992 and no. 26, G.U., 03-04-2014) and 
international law and policies (EEC, Council Directive nos. 2010/63/EU, OJ L 
276/33 and 09-22-2010; National Institutes of Health Guide for the Care and Use 
of Laboratory Animals, US National Research Council, 2011). "e study was 
approved by the Italian Ministry of Health (nos. 97/2014-PR and 25/2018-PR). All 
e!orts were made to minimize the number of animals used and their su!ering.
Cells. The following mycoplasma-free cell lines were used: 3-MCA-derived 
sarcoma cell line MN/MCA1 and melanoma cells B16/F10 and K1735-M2. B16/
F10 cells were purchased from ATCC; K1735-M2 cells were kindly provided 
by L. Carminati (Laboratory of Tumor Microenvironment, Istituto di Ricerche 
Farmacologiche Mario Negri IRCCS, Bergamo, Italy). The 3-MCA-derived 
sarcoma cell line MN/MCA1 was derived from stock periodically renewed through 
primary cells isolated from tumors implanted in WT mice. All cell lines were 
mycoplasma-free. Nfr2%/% BM cells derived from Nfe2l2%/% mice were available from 
M. P. Soares (Inflammation Laboratory, Instituto Gulbenkian de Ciência, Oeiras, 
Portugal)43.
Cancer models. Mice were injected intramuscularly in their left hindlimb with 
3-MCA-derived, mycoplasma-free sarcoma cell line MN/MCA1 (105 or 104 cells 
per mouse in 100 &l of PBS). From day 14 after tumor cell injection, primary 
tumor growth was monitored three times per week with a caliper. Mice were 
subcutaneously injected with 100 &l of PBS containing 5 ( 105 murine melanoma 
B16/F10 cells. Ten days after tumor cell injection, tumor growth was monitored 
three times per week with a caliper. For spontaneous lung metastasis assay, 
mice were subcutaneously injected with 100 &l of PBS containing 5 ( 105 murine 
melanoma B16/F10 cells. Growth of the primary tumor was monitored with a 
caliper and, when tumors reached 0.8–1.0 cm3, mice were anesthetized and tumors 
surgically removed; for analysis of spontaneous lung metastasis, all mice were 
autopsied 30 days after surgery. Melanoma K1735-M2 (105 cells per mouse) were 
implanted subcutaneously in the flank of C3H/HeN mice. Growth of the primary 
tumor was monitored with a caliper and, when tumors reached 800–1,000 mm3, 
mice were anesthetized and tumors surgically removed; for analysis of spontaneous 
lung metastasis, all mice were autopsied 30 days after surgery. Hmox1fl/fl and 
Hmox1fl/flLyz2-Cre mice were injected intramuscularly in the left hindlimb with 
MN/MCA1 mCherry+ (105 cells per mouse in 100 &l of PBS); blood was collected 
20 days after tumor cell injection and analyzed by RT–PCR for mCherry expression 
and by FACS for circulating MN/MCA1 mCherry+ tumor cell quantification.
In vivo treatments. From day 10 after tumor cell injection, MN/MCA1-bearing 
mice were treated intraperitoneally with a CSF1R antagonist (a kind gift from 
C. Ries, Roche Diagnostic, Penzberg, Germany) at an initial dose of 60 mg kg–1, 
followed by twice-weekly doses of 30 mg kg–1 for the duration of the experiment. 
Control mice were injected with an isotype antibody. From day 7 post implantation, 
MN/MCA1-bearing mice were intraperitoneally injected with 30 mg kg–1 ZnPPIX 
(Frontier Scientific) three times per week. When specified, starting from the day 
before tumor injection, mice received an intraperitoneal injection of 0.3 mg of 
anti-mouse CD4 (Rat Anti-Mouse CD4 Monoclonal Antibody, Unconjugated, 
Clone GK1.5, BioXcell) and 0.3 mg of anti-mouse CD8 (Rat Anti-Mouse CD8$ 
Monoclonal Antibody, Unconjugated, Clone 2.43, BioXcell) once per week 
for the duration of the experiment. FACS analysis of peripheral blood samples 
confirmed depletion of CD4+ and CD8+ cells over 7 days. B16-bearing mice were 
intraperitoneally injected with 30 mg kg–1 ZnPPIX (Frontier Scientific) from day 3 
post implantation, three times per week, either separately or in combination with 
100 µg of anti-PD-1 antibody (Clone RPM1-14, BioXcell), twice per week, starting 
9 days after tumor cell injection. For the spontaneous metastasis assay, ZnPPIX 
(30 mg kg–1, intraperitoneally, 2 days per week) was given before and after surgical 
removal of K1735-M2 primary melanomas44, performed when tumors had reached 
a mean volume of 1 cm3; all mice were autopsied 30 days postoperatively. To induce 
LPS tolerance in vivo, 8-week-old WT and p50–/– mice, weighing approximately 
20 g, were injected intraperitoneally with 200 &g of LPS (from Escherichia coli strain 
B05.55; Sigma). Blood was collected 0, 6 and 24 h following LPS injection for flow 
cytometry analysis. From day 7 after tumor cell injection, MN/MCA1-bearing 
mice were treated intraperitoneally with 2 mg kg–1 brusatol (Sigma, catalog no. 
SML1868), three times per week for the duration of the experiment.
Lung histology. Lungs were collected following intracardiac perfusion with 
cold PBS and were formalin fixed for 24 h, dehydrated and paraffin embedded 
for histologic analysis. Histology was performed on longitudinal serial sections 
(100 &m apart, width 8 &m) from each lung, stained with hematoxylin and eosin 
(H&E) and scanned using a VS120 Dot-Slide BX61 virtual slide microscope 
(Olympus Optical). The area of lung lesions was obtained by manual tracing of the 
perimeter of lesions using Image Pro-Premiere software 9.2 (Media Cybernetics).
Adoptive transfer experiments. FACS-sorted F4/80hiC5aR1hi and F4/80loC5aR1lo 
TAMs (2 ( 105) from WT MN/MCA1 sarcomas were injected intramuscularly, 
together with 105 MN/MCA1 tumor cells, into the hindlimb of WT or p50–/– mice. 
After sacrifice, lungs were fixed and macroscopic metastases enumerated.
Generation of BM chimeras. CD45.2 WT mice were lethally irradiated with 
a total dose of 900 cGy. Two hours later, mice were injected in the retro-orbital 
plexus with 5 ( 106 nucleated BM cells, isolated by flushing the cavity of a freshly 
dissected femur from CD45.1 WT donors. Ten days before irradiation, recipient 
mice received gentamycin (0.8 mg ml–1 in drinking water), which was administered 
for an additional 2 weeks. BM reconstitution was evaluated 6 weeks after 
transplantation by flow cytometry of peripheral blood and was deemed positive if 
>90%. Eight weeks after BM transplantation, mice were injected with MN/MCA1 
tumor cells.
Patients. Human peripheral blood leukocytes were isolated from two consecutive 
cohorts (discovery and confirmation) of stage IIIC/IV (AJCC melanoma staging 
system, eighth edition), undergoing surgical treatment for metastatic melanoma 
at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy between 
November 2001 and September 2003. Samples from the cohorts described in 
this study were obtained based on informed consent. The study was conducted 
according to the Declaration of Helsinki Principles and following approval by the 
Ethics Committee of Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, 
Italy. The main clinical parameters, including type of therapy after isolation of 
peripheral blood lymphocytes of all patients, are listed in Supplementary Table 
2. The discovery set (n = 47) included patients in AJCC stages IIIC (n = 35) and 
IV (n = 12). The confirmation set (n = 45) included patients in AJCC stages IIIC 
(n = 31) and IV (n = 14).
FACS analysis of human samples. Human peripheral mononuclear cells 
were obtained by Ficoll density gradient centrifugation (Ficoll-Paque PLUS, 
GE Healthcare). Multicolor staining for cell populations was performed on 
cryopreserved samples. Cells were thawed in RPMI medium supplemented with 
10% human serum; 2 ( 106 lymphocytes were resuspended in 100 &l of staining 
buffer (PBS + 2% fetal bovine serum (FBS)) and incubated with FcR Blocking 
Reagent (Miltenyi Biotec) with antibodies against the indicated cell surface markers 
and Zombie Aqua (Fixable viability dye, Biolegend) in staining buffer for 30 min at 
4 °C. The following human antibodies were used: CD14-PE-CF594 (M5E2) (1/200, 
Biolegend catalog no. 301851, CD3-PerCP-Cy5.5 (UCHT1) (1/100, Biolegend 
catalog no. 300430), CD16-PE-Cy7 (3G8) (1/400, Biolegend catalog  
no. 302015), CD45-BV421 (HI30) (1/200, Biolegend catalog no. 304032),  
CD88-PE (S5/1) (1/200, Biolegend catalog no. 344303), CD19-PerCP-Cy5.5 
(SJ25C1) (1/100, Biolegend catalog no. 363015), CD56-PerCP-Cy5.5 (5.1H11) 
(1/100, Biolegend catalog no. 362505), Tie2/CD202b-Alexa Fluor 647 (33.1) 
(1/200, Biolegend catalog no. 334209) and HMOX1 FITC (1/200, Abcam catalog 
no. ab69545).
Cell permeabilization was obtained with a Cytofix/Cytoperm Fixation/
Permeabilization Solution Kit (BD Pharmingen) according to the manufacturer’s 
instructions. After permeabilization, cells were stained with HO-1 mAb (FITC, 
Abcam catalog. no. ab69545) for 30 min at 4 °C and acquired by a ten-color 
Gallios (Beckman Coulter) cytometer. Instrument optical alignment and fluidics 
were routinely checked by Flow-Check Fluorospheres (Beckman Coulter), while 
Flow-Set Fluorospheres (Beckman Coulter) were used for control of light scatter 
and fluorescence intensity. Data were analyzed with FlowJo software (v.10.5.3, 
FlowJo, LLC) after exclusion of doublets (on SSC-A versus SSC-H dot plots) and 
by gating on live (Zombie Aqua-) cells. Fifteen monocyte subsets were identified 
by staining for CD14, CD16, CD88 and Tie2 (subsets R1–R3 and R1R5–R3R8) 
with the gating strategy shown in Extended Data Fig. 7a. All subsets expressed 
intracellular HO-1, recorded as gMFI in permeabilized cells (Extended Data 
Fig. 7b). The distribution of HO-1 gMFI values for all monocyte subsets, in 
both discovery and confirmation cohorts, did not pass the D’Agostino–Pearson 
Normality test (alpha = 0.05; Supplementary Table 2b). Within each monocyte 
subset, HO-1 gMFI values showed no significant differences when comparing 
discovery and confirmation cohorts (Mann–Whitney test; Supplementary Table 
2c). However, distinct monocyte subsets showed significant differences in the 
combined set of gMFI HO-1 values (Kruskal–Wallis test followed by Dunn’s 
multiple comparison test; Extended Data Fig. 7c).
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FACS analysis of murine samples. Primary tumors were cut into small pieces, 
disaggregated with 0.5 mg ml%1 COL IV and 150 U ml%1 DNase I in RPMI 1640 for 
30 min at 37 °C and filtered through strainers. Macroscopic lung metastatic lesions 
were removed with tweezers. Pulmonary nodules isolated were finely minced, 
disaggregated with 0.5 mg ml%1 COL IV and 150 U ml%1 DNase I in RPMI 1640 for 
30 min at 37 °C and filtered through Falcon strainers (70 µm). Splenocytes were 
collected from spleens after disaggregation and filtration through Falcon strainers 
(70 µm). Livers were removed, cut into small pieces and gently mashed through a 
cell strainer (70 µm) followed by enrichment of the leukocyte population on a 35% 
Percoll gradient (Sigma). BM cells were isolated from the tibias and femurs of both 
tumor-free and tumor-bearing mice. Whole blood samples were collected from 
the facial vein or heart in EDTA-coated collection tubes and directly processed 
using a standardized red blood cell lysis protocol. Cells were resuspended in Hank’s 
balanced salt solution (Lonza) supplemented with 0.5% bovine serum albumin 
(BSA) (Sigma-Aldrich). Staining was performed at 4 °C for 20 min with the 
following mouse antibodies:
CD45-FITC (30-F11) (1/400, Biolegend catalog no. 103108); CD45-PerCP 
(30-F11) (1/200, Biolegend catalog no. 103130); CD45-BUV563 (30-F11) 
(1/400, BD Horizon catalog no. 565710); CD45.1-APC (A20) (1/200, Biolegend 
catalog no. 110714); CD45.2-FITC (104) (1/200, Biolegend catalog no. 109806); 
CD11b-PerCp-Cy5.5 (M1/70) (1/200, eBioscence catalog no. 45-0112-82); 
CD11b-PE (M1/70) (1/400, Biolegend catalog no. 101208); CD11b-FITC 
(M1/70) (1/200, Biolegend catalog no. 101206); CD11b-BV711 (M1/70) 
(1/600, Biolegend catalog no. 101242); F4/80-APC (BM8) (1/100, Biolegend 
catalog no. 123116); F4/80-PE (BM8) (1/200, Biolegend catalog no. 123110); 
F4/80-PE-Cy7 (BM8) (1/200, Biolegend catalog no. 123114); F4/80-BV421 
(BM8) (1/100, Biolegend catalog no. 123137); Ly6G-PE (1A8) (1/200, Biolegend 
catalog no. 127608); Ly6G-BV570 (1A8) (1/100, Biolegend catalog no. 
127629); Ly6C- APC-Cy7 (HK1.4) (1/600, eBioscence catalog no. 47-5932-82); 
MHCII-PE-Cy7 (M5/114.15.2) (1/200, eBioscence catalog no. 78-5321-82); 
MHCII-PE (M5/114.15.2) (1/400, Biolegend catalog no. 107607); MHCII-BV480 
(M5/114.15.2) (1/600, BD Horizon catalog no. 566088); CD11c-APC (N418) 
(1/100, Biolegend catalog no. 117310); CD11c-BV605 (N418) (1/200, eBioscence 
catalog no. 63-0114-82); CD8-APC (53-6.7) (1/100, Biolegend catalog no. 
100712); CD8-BUV805 (53-6.7) (1/200, BD Horizon catalog no. 564920); CD4-PE 
(GK1.5) (1/200, Biolegend catalog no. 100408); CD4-PE-Cy7 (GK1.5) (1/200, 
Biolegend catalog no. 100422); CD4-BUV496 (GK1.5) (1/100, BD Horizon catalog 
no. 564667); CD3-PerCP (145-2C11) (1/100, Biolegend catalog no. 100326); 
CD3-BV650 (145-2C11) (1/100, Biolegend catalog no. 100229); IFN"-FITC 
(XMG1.2) (1/100, Biolegend catalog no. 505806); IFN"-PE (XMG1.2) (1/200, 
BD Pharmingen catalog no. 554412); FoxP3-Alexa Fluor 488 (MF23) (1/100, 
BD Pharmingen catalog no. 560403); FoxP3-Alexa Fluor 647 (MF23) (1/100, BD 
Pharmingen catalog no. 560402); CD115-PE (AFS98) (1/100, Biolegend catalog 
no. 135505); CD115-APC (AFS98) (1/50, Biolegend catalog no. 135510); CD31-PE 
(MEC 13.3) (1/100, BD Pharmingen catalog no. 553373); Tie2 CD202b-PE 
(TEK4) (1/200, eBioscence catalog no. 12-5987-81); CD88-PE (20/70) (1/200, 
Biolegend catalog no. 135806); CD88-APC (20/70) (1/100, Biolegend catalog 
no. 135808); CCR2-Alexa Fluor 647 (SA203G11) (1/100, Biolegend catalog no. 
150603); CCR2-PE-Cy7 (SA203G11) (1/100, Biolegend catalog no. 150612); 
HO-1-PE (HO-1-2) (1/200, EnzoLifeSciences catalog no. ADI-OSA-11PE-F); 
CX3CR1-PE (SA011F11) (1/200, Biolegend catalog no. 149005); CD195 
(CCR5)-PE (HM-CCR5) (1/100, Biolegend catalog no. 107005); TNF$-Alexa 
Fluor 647 (MP6-XT22) (1/100, BD Pharmingen catalog no. 557730); CD206-APC 
(C068C2) (1/100, Biolegend catalog no. 141708); CD64-APC (X54-5/7.1) (1/100, 
eBioscence catalog no. 17-0641-82); CD16/32-APC (93) (1/100, eBioscence 
catalog no. 17-0161-82); Hematopoietic Lineage-eFluor 450 (1/400, eBioscence 
catalog no. 88-7772-72); CD34 FITC (RAM34) (1/100, BD Pharmingen catalog 
no. 560238); Gr1-FITC (RB6-8C5) (1/50, BD Pharmingen catalog no. 553127); 
CD44-FITC (IM7) (1/100, Biolegend catalog no. 103006); CD62L-APC (Mel-14) 
(1/100, BD Pharmingen catalog no. 553152); CD62L-BV570 (Mel-14) (1/100, 
Biolegend catalog no. 104433); SiglecF-FITC (S17007L) (1/100, Biolegend catalog 
no. 155504); SiglecF-Alexa Fluor 700 (E50-2440) (1/50, BD Bioscence catalog no. 
562680); Ki67-APC (16A8) (1/100, Biolegend catalog no. 652405); VEGFR-PE-Cy7 
(Avas12) (1/200, Biolegend catalog no. 136414); CD163-Super Bright 702 
(TNKUPJ) (1/100, eBioscence catalog no. 67-1631-82); E-Cadherin-BV421 
(DECMA-1) (1/100, Biolegend catalog no. 147319). We also used unconjugated 
goat polyclonal anti-C3aR (D-20) (1/200, Santa Cruz Biotechnology catalog 
no. sc-14624); rabbit anti-pSTAT1 (58D6) (1/200, Cell Signaling catalog no. 
9167); rabbit anti-pSTAT3 (M9C6) (1/200, Cell Signaling catalog no. 4113); 
rabbit anti-pSTAT6 (D8S9Y) (1/200, Cell Signaling catalog no. 56554); Nrf2 
rabbit polyclonal antibody (1/100, ThermoFisher catalog no. PA5-27882); VEGF 
rabbit polyclonal antibody (SP07-01) (1/100, ThermoFisher catalog no. MA5-
32038); Vimentin rabbit monoclonal antibody (SP20) (1/100, ThermoFisher 
catalog no. MA5-14564); N-Cadherin rabbit monoclonal antibody (3B9) (1/100, 
ThermoFisher catalog no. 33-3990); and anti-HIF1$ rabbit monoclonal antibody 
(16H4L13) (1/100, ThermoFisher catalog no. 700505), followed by incubation 
with secondary donkey anti-goat Alexa Fluor 647-conjugated antibody (1/500, 
ThermoFisher catalog no. A-21447), goat anti-rabbit Alexa Fluor 488-conjugated 
antibodies (1/500, ThermoFisher catalog no. A-11008) and goat anti-rabbit Alexa 
Fluor 647-conjugated antibodies (1/500, ThermoFisher catalog no. A27040). Cell 
viability was determined by either Aqua LIVE/Dead-405-nm staining (1/800, 
Biolegend catalog no. 423102) or LIVE/DEAD Fixable Violet Dead Cell Stain Kit 
(1/1,000, ThermoFisher catalog no. L34960); negative cells were considered viable. 
A Foxp3/Transcription Factor Staining Buffer Set (eBioscience) was used for 
intracellular staining of TNF-$, IFN", Foxp3 and CD206. Expression of TNF-$ and 
IFN-" was analyzed by flow cytometry following 4 h of treatment with brefeldin A 
(5 &g ml%1), PMA (50 ng ml%1) and ionomycin (1 &g ml%1). Cells were detected using 
either BD FACSCanto II, BD LSRFortessa or BD FACSymphony and analyzed 
with BD FACSDiva and FlowJo (9.3.2 and 9.9.6, respectively) software. Results are 
reported as MFI normalized on isotype control or fluorescence minus one.
Purification of mouse leukocytes. Thioglycollate-elicited PECs were isolated 
from healthy mice as previously described3. PECs were cultured in RPMI 1640 
medium supplemented with 10% FBS, 2 mM glutamine and 100 U ml–1 penicillin/
streptomycin. To induce LPS tolerance, cells were incubated in the presence of LPS 
(100 ng ml–1) (LPS from Salmonella abortus Equi S-form; Alexis) for 20 h, washed, 
maintained in RPMI medium for 2 h and then rechallenged with LPS for 4 h (LPS/
LPS, L/L). To induce M1 activation, cells were incubated in medium for 20 h, 
washed, left in medium for 2 h and finally stimulated with LPS for 4 h (medium/
LPS, M/L). Control cells (medium/medium, M/M) were cultured in medium for 
the duration of the experiment. Where indicated, PECs were pretreated with either 
ZnPPIX (2 &M, Frontier Scientific) or CORM-2 (10 &M, Frontier Scientific) for 2 h 
before induction of LPS tolerance. Where indicated, PECs from WT or p50–/– mice 
were treated with 100 ng ml–1 of either C3a (R&D Systems) or M-CSF (Peprotech) 
for 24 and/or 48 h.
Primary tumors were cut into small pieces, disaggregated with 0.5 mg ml%1 
COL IV and 150 U ml%1 DNase I in RPMI 1640 for 30 min at 37 °C and filtered 
through strainers. TAMs isolated 3–4 weeks after tumor implantation, as previously 
described45, were enriched by positive selection using CD11b microbeads (MACS, 
Miltenyi Biotec) according to the manufacturer’s instructions. The purity of 
CD11b+ cells was ~90% as determined by FACS. To obtain high-purity TAM 
populations (that is, F4/80hiC5aR1hi and F4/80loC5aR1lo, respectively), CD11b+ cells 
were stained (CD45-PerCP, F4/80-APC, CD88-PE) and sorted on a FACSAria cell 
sorter (BD Bioscience). The purity of each population was )90%. The resulting 
cells were either processed for mRNA extraction or used for adoptive transfer or 
migration experiments in vitro.
Quantitative PCR. Total RNA was extracted using Trizol reagent (Invitrogen) 
following the manufacturer’s instructions. Complementary DNA was synthesized 
by reverse transcription using a High Capacity cDNA Archive Kit (Applied 
Biosystems), and quantitative real-time PCR was performed using SybrGreen PCR 
Master Mix (Applied Biosystems) in a 7900HT Fast Real-Time System (Applied 
Biosystems). Data were processed using SDS v.2.2.2 software (Applied Biosystems) 
and analyzed with the 2(%*CT) method. Data were normalized to !-actin or GAPDH 
expression. Primer sequences used in the manuscript are available upon request.
Confocal microscopy. Frozen tissues in OCT (optimal cutting temperature 
compound) were sectioned (8 &m), mounted on positively charged slides, air-dried 
for 30 min and fixed with 4% paraformaldehyde for 10 min at room temperature. 
Sections were permeabilized with 0.1% Triton X-100 and incubated with blocking 
buffer (5% normal goat serum, Sigma-Aldrich, 2% BSA, 0.05% Tween). Slides were 
then stained with rabbit anti-mouse/human HO-1 (1 µg ml–1; Bio-Rad catalog no. 
4915-1050) and rat anti-mouse F4/80 (1 µg ml–1; Bio-Rad catalog no. MCA497R) 
or rabbit anti-mouse CD31 (0.5 µg ml–1; PECAM-1, Pharmingen) followed 
by Alexa Fluor 488-conjugated goat anti-rabbit IgG (1/1,000, ThermoFisher, 
catalog no. A-11008) and Alexa Fluor 647-conjugated goat anti-rat IgG antibody 
(1/1,000, ThermoFisher catalog no. A21-247). Nuclei were counterstained with 
DAPI (Invitrogen catalog no. D1306). Coverslips were mounted with the antifade 
medium FluorPreserve Reagent (EMD Millipore) and analyzed with an Olympus 
Fluoview FV1000 (FV10-ASW 3.0) laser scanning confocal microscope using 
the fine-focus oil immersion lens ((4/1.3 numerical aperture (NA)) at resolution 
of 1 Airy unit and operating in channel mode with excitation 405 and 633 nm 
((4/1.3 NA Plan-Apochromat; Olympus).
Immunoblotting. After the indicated treatments, PECs or TAMs were lysed in 
50 &l of lysis buffer (20 mM Tris-HCl pH 8.0, 137 mM NaCl, 10% glycerol (vol/
vol), 1% Triton X-100 (vol/vol), 1 mM Na3VO4, 2 mM EDTA, 1 mM phenylmethyl 
sulfonyl fluoride, 20 &M leupeptin and 0.15 U ml–1 aprotinin) for 20 min at 4 °C. 
The lysates were centrifuged at 13,000g at 4 °C for 15 min, and the supernatants 
were run on 10% (wt/vol) SDS–polyacrylamide gel electrophoresis (SDS–PAGE; 
30 &g of protein per lane). Separated proteins were transferred to a nitrocellulose 
membrane and immunoblotted for specific antibodies according to the 
manufacturer’s instructions. The following antibodies were used: (primary) rabbit 
anti-mouse phospho-p44/42 MAPK (Erk1/2; Cell Signaling Technologies) and goat 
anti-mouse vinculin (Santa Cruz Biotechnology); (secondary) goat anti-mouse and 
anti-rabbit IgG horseradish peroxidase (HRP)-conjugated (Amersham). ImageLab 
Software v.4.1 (Bio-Rad) was used for image acquisition and densitometric analysis 
of blots.
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In vitro migration assay. Migration of PECs and TAMs was evaluated using 
a previously described chemotaxis microchamber technique4. Briefly, 30 &l of 
100 ng ml–1 chemoattractant solution (C5a or C3a, both R&D Systems) in RPMI 
1640 with 1% FBS, or control medium (RPMI 1640 with 1% FBS), was added to the 
lower wells of a chemotaxis Boyden chamber (Neuroprobe) and a polycarbonate 
filter (polyvinyl polypyrrolidone-treated, 5 &m pore size; Neuroprobe) was placed 
in the wells and covered with a silicon gasket. The correct concentration for each 
cytokine used was determined by dose–response assay using WT or p50–/– cells 
(Extended Data Fig. 1c). Fifty microliters of cell suspension (4 ( 106 ml–1) was 
seeded in the upper wells and the chamber was incubated at 37 °C for 4 h. Filters 
were then removed and stained with Diff-Quik (Baxter). Ten high-power oil 
immersion fields were counted.
Immunohistochemistry and image analysis. Immunohistochemistry on 
formalin-fixed, paraffin-embedded (PFPE) tissues from human melanoma lesions 
was performed as described previously46. Sections were stained with antibodies to 
CD3 (no. NCL-L-CD3-PS1, Leica Biosystems), CD68 (no. M0814, Dako), CD163 
(no. NB110-59935, Novus Biologicals) and HO-1 (no. ab13248, Abcam). Images 
were acquired at (20 with an Aperio Scanscope XT digital pathology slide scanner 
(Leica Biosystems). Quantitative assessment of HO-1+ cells was performed using 
open source QuPath software v.0.1.2. Files in .svs format, generated by Aperio 
Scanscope, were preprocessed by the ‘auto detect’ function of the visual stain editor 
to estimate staining vectors after selection of an area containing background and 
strong hematoxylin and DAB staining. Regions of interest (ROI), each containing 
at least 10,000 cells and collectively representing an average surface area of 
2–3 mm2 of each lesion, were defined for subsequent positive cell detection. The 
score compartment was ‘cytoplasm DAB OD mean’ for HO-1 staining. A single 
threshold for intensity (0.2) was adopted. QuPath annotation measurements, 
including number of negative or positive cells and area (in &m2) of each ROI, were 
exported to Excel for further analysis. For anti-mouse CD31, F4/80 and HO-1, 
PFPE mouse tumor tissues were mounted on Super-frost slides, dewaxed in xylene 
and rehydrated in ethanol. Endogenous peroxidases were blocked for 20 min with 
2% H2O2. Unspecific binding sites were blocked with PBS + 2% BSA for 1 h. Tissues 
were incubated for 2 h with affinity-purified immunoglobulin against CD31 
(0.5 µg ml–1 PECAM-1, Pharmingen), anti-mouse F4/80 (Clone CI:A3-1, 1/500, 
Bio-Rad catalog no. MCA497R) or anti-mouse HO-1 (1/500, Bio-Rad catalog no. 
4915-1050) in PBS supplemented with BSA (2%). Either a Rat-on-Mouse HRP 
polymer kit (no. RT517H, Biocare Medical) or MACH1 Universal HRP polymer 
detection kit (no. M1U539 G, Biocare Medical) was used as secondary antibody. 
Reactions were developed with 3,3-diaminobenzidine (Biocare Medical) and slides 
were then counterstained with hematoxylin and mounted with Eukitt mounting 
medium (Sigma-Aldrich).
In vivo vascular permeability assay and confocal microscopy. FITC–labeled 
40-kDa dextran (0.25 mg per mouse; ThermoFisher Scientific/Life Technologies) 
was administered intravenously by retro-orbital injection into anesthetized MN/
MCA1-bearing mice. Thirty minutes after injection, mice were perfused with PBS 
and tumors were fixed in 2% paraformaldehyde and embedded in OCT. Specimens 
were permeabilized with 0.1% Triton X-100 and incubated with blocking buffer 
(5% normal goat serum (Sigma-Aldrich), 2% BSA, 0.05% Tween). The following 
primary antibodies were used: rat anti-mouse CD31 (no. MEC 13.3, 0.5 µg ml–1; 
BD Biosciences), Cy3TM-labeled anti-$-SMA (no. 1A4, 2 µg ml–1; Sigma-Aldrich) 
and rabbit anti-COL IV (no. PA1-28534, 1 µg ml–1; ThermoFisher Scientific). A 
goat anti-rat antibody conjugated with Alexa Fluor 647 (ThermoFisher Scientific, 
catalog no. A21-247) and a goat anti-rabbit antibody conjugated with Alexa 
Fluor 532 (ThermoFisher Scientific, catalog no. A11-009) were respectively 
used to detect CD31 and COL IV. Coverslips were mounted with the antifade 
medium FluorPreserve Reagent (EMD Millipore) and analyzed with a Leica 
SP8 STED3X confocal microscope system and a multi-immersion HP PL (20/
NA 0.75 lens equipped with a white light laser (Leica Microsystems). Images 
(xyz, 1,024 ( 1,024 pixels) were acquired in unidirectional mode as a mosaic 
(15–30 images per condition) to cover entire tumor specimens and were analyzed 
as a maximum-intensity projection. A similar background correction was applied 
to all samples for each staining. Vessel leakiness under different conditions was 
assessed as colocalization rate between the extracted signal of CD31+ and FITC+ 
pixels by LASX software (v.3.5.7, Leica Microsystems), using the same threshold 
and expressed percentage of colocalization material. Similarly, pixels referring 
to markers of vessel stability, $-SMA and COL IV, were separately analyzed as 
colocalization rate with CD31+ vessels.
Microarray analysis. Total RNA was extracted from 1–5 ( 106 PECs and F4/80hi 
and F4/80lo TAMs (RNeasy kit, Qiagen) according to standard methods. Samples 
were amplified, labeled using the Agilent Quick Amp labeling kit and hybridized 
using Agilent SurePrint G3 Mouse GE 8x60K Microarray (no. G4852A-028005, 
Agilent Technologies) and Agilent SureHyb hybridization chambers. Three 
independent replicate experiments were performed for each group. Scanned 
images were analyzed with Feature Extraction Software (v.10.7, Agilent 
Technologies) using default parameters to obtain filtered, background-subtracted 
and quantile-normalized spatially processed signal intensities. log2 normalized 
intensity signals were imported into R software (v.3.5.1) with Bioconductor 
(v.3.8) and further processed with the limma package (v.3.38)47. The BiomaRt 
package (v.2.40)48 was used to annotate probe ID with the Agilent SurePrint G3 
GE 8 ( 60-k probe annotation set. Resulting log2 normalized intensity values for 
the 9.703 unique probes and corresponding genes are provided in Supplementary 
Table 1. Differential expression analysis: the limma package was used to calculate 
fold changes and P values for differential expression using the empirical Bayes 
statistics for differential expression (eBayes) framework. A probe was considered 
significantly differentially expressed if it had an absolute value of fold change )1.5 
and adjusted P ' 0.05. A complete list of all 5,587 differentially expressed genes is 
provided in Supplementary Table 1. Hierarchical clustering and heatmaps were 
performed using the pheatmap R package (v.1.0.12); Principal component analysis 
was performed using the R packages factoextra (v.1.0.6) and FactoMineR (v.1.42). 
Gene expression levels were centered on the mean and normalized. Clustering was 
done using complete linkage with Euclidean distance as the metric. GO analysis 
was done with enrichGO from the R package ClusterProfiler (v.3.10.1)49 providing 
the GO gene set (c5.bp.v.6.2) retrieved from the Molecular Signatures Database50. A 
term was considered significantly enriched with adjusted P ' 0.1.
Statistics and survival analysis. Data relative to patients and biomarker (HO-1 
gMFI values in 15 monocyte subsets) characteristics are presented by group 
(discovery, confirmation) and overall. Summary measures were relative and 
absolute frequencies for categorical data, and mean median range and interquartile 
range for continuous data. Comparison of biomarker distribution between groups 
was conducted by means of the Wilcoxon test for independent groups. Association 
of biomarkers with survival was tested by a semiparametric Cox regression model 
in both the univariate and multivariable approach, adjusted for postoperative 
therapy (at the time of blood sample isolation). Hazard ratio relative to a variation 
per unit of the scale was calculated, together with 95% confidence interval and 
associated P value. Analysis was conducted in the discovery group and then 
validated in the confirmation group. Kaplan–Meier survival curves were calculated 
for each biomarker (HO-1 gMFI value in each of the 15 monocyte subsets), 
considering the overall median of the distribution of values of each biomarker 
as the cutoff point for dichotomization. Deviation from Gaussian distribution of 
HO-1 gMFI values of all monocyte subsets was assessed using the D’Agostino–
Pearson omnibus normality test. Comparison of discovery and confirmation sets 
for HO-1 gMFI values in monocytes was carried out by Mann–Whitney test. 
Comparison of multiple samples was carried out by Kruskal–Wallis test followed 
by Dunn’s multiple comparison tests. Survival was defined as the time (days) from 
peripheral blood isolation (coincident with surgery for metastatic disease) to death 
or the date of last information on patient status. For animal studies, sample size 
was defined based on experience on cancer and infection models, which enabled 
us to detect differences of 20% or greater between groups (10% I-type error and 
80% power). Values are expressed as either mean ± s.e.m. or median of biological 
replicates. Either one-way ANOVA or a Kruskal–Wallis test was used to compare 
multiple groups. A two-tailed, unpaired Student’s t-test was used to compare 
unmatched groups with Gaussian distribution. A Mann–Whitney U-test was used 
in cases of non-Gaussian distribution. Two-way ANOVA corrected for multiple 
comparison by &idák’s test was used to take into account multiple comparisons. 
P ' 0.05 was considered statistically significant. Statistical analyses were performed 
with GraphPad Prism v.7 GraphPad Software and SAS software, v.9.4 (SAS 
Institute).
Timer analysis. Results of the multivariable Cox proportional hazards model 
on the TCGA skin cutaneous melanoma dataset were obtained through 
the outcome module of the TIMER2.0 web server (available at http://timer.
comp-genomics.org)51 by testing the relevance of tumor-infiltrating macrophages, 
as identified by the M2_TIDE macrophage signature52, and of the expression of 
macrophage-related genes CD163, HMOX1 and CD68.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the 
corresponding author upon reasonable request. RNA-seq raw data are reported in 
Supplementary Table 1 and have been deposited at the Gene Expression Omnibus 
(GEO accession no. GSE167413). Datasets containing patients’ clinical parameters 
and flow cytometry data generated during the current study are presented in 
Supplementary Tables 2 and 3.
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Extended Data Fig. 1 | Role of NF-!B1 in macrophage migration. a, FACS analysis of C5aR1, and C3aR in WT and p50–/– PECs (+=variation compared to 
isotype control), n!=!4 mice per genotype; shown are data representative of two independent experiments. b, Boyden-chamber migration assay of WT and 
p50–/– PECs in response to C3a or C5a; shown are pooled data from n!=!2 experiments with n!=!3 animals per group. c, Bell-shaped curve migration of WT 
and p50–/– PECs in response to C3a and C5a, for each condition, cells pooled from n!=!3 mice were used; one experiment was performed.  
d, Phospho-ERK1/2 levels in WT and p50–/– PECs treated with C3a, C5a or LPS, for each condition, cells pooled from n!=!3 mice were used; one experiment 
was performed. e, Chemotactic activity of WT PECs: untreated (M/M); LPS-activated: 20 h medium plus 4 h LPS (M/L); LPS-tolerant: 20 h LPS plus 4 h 
restimulation with LPS (L/L); medium and C5a: shown are pooled data from n!=!2 experiments with n!=!3 animals per group, C3a: n!=!3 mice were used, 
one experiment was performed. f, immunoblot analysis of phospho-ERK1/2 in M/M, M/L and L/L PECs in response to C3a or C5a treatment, for each 
condition, cells pooled from n!=!3 mice were used; one experiment was performed. g, Boyden-chamber migration assay of TAMs (CD45+F4/80+CD11b+) 
FACS-sorted from WT or p50–/– MN/MCA1 tumor-bearing mice. For each condition, cells pooled from n!=!3 mice were used; one experiment was 
performed. Data are mean ± SEM. *P!<!0.05 **P!<!0.01 ***P!<!0.001, ****P!<!0.0001 between selected relevant comparisons. In a-g, two-way ANOVA with 
Sidak’s multiple comparisons test.Source data
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Extended Data Fig. 2 | Impact of F4/80hi TAMs accumulation on metastasis formation and tumor angiogenesis. a, area of metastatic burden quantified 
from H&E stained lung sections from WT MN-MCA1-bearing mice treated with vehicle or anti-CSF1R is expressed as a percentage of total lung surface 
area. Representative images are shown. Scale bars, 1!mm. n!=!4 (Vehicle) and n!=!5 (anti-CSF1R), one experiment was performed. b, FACS quantification 
of CD31+ cells in lung metastasis of WT MN-MCA1-bearing mice treated with vehicle or anti-CSF1R; n!=!5 (Vehicle) and n!=!4 (anti-CSF1R), shown are 
data representative of two independent experiments. c, Representative H&E stained lung sections from WT and C3–/– MN-MCA1-bearing mice and 
quantification of area of metastatic burden expressed as a percentage of total lung surface area. Scale bars, 1!mm. n!=!3 (Vehicle) and n!=!5 (C3–/–), one 
experiment was performed. d, FACS quantification of CD31+ cells in lung metastasis of WT and C3–/– MN-MCA1-bearing mice; n!=!5 (Vehicle) and n!=!4 
(C3–/–), shown are data representative of two independent experiments. e, Representative images of MN/MCA1 tumor sections from WT, C3–/– and 
anti-CSF1R treated mice injected with FITC-Dextran. Sections were co-stained for FITC-Dextran (green) and CD31 (red) (top left); quantification of 
vascular permeability expressed as percentage of colocalization rate between extracted signal of CD31+ and FITC+ pixels (bottom left). Representative 
images of MN/MCA1 tumor sections from WT, C3–/– and anti-CSF1R treated mice costained for collagen IV (green), CD31 (red) and $-SMA (white) (top 
right); quantification of vessel stability was assessed as colocalization rate of Collagen IV+ or $-SMA+ with CD31+ vessels (bottom right); scale bars, 
10!&m; n!=!3 mice per genotype, one experiment was performed. Data are mean ± SEM. *P!<!0.05 **P!<!0.01 ***P!<!0.001, ****P!<!0.0001 between selected 
relevant comparisons. In a-d, two-tailed unpaired Student’s t-test. In e, one-way ANOVA and Kruskal-Wallis test with Dunn’s multiple comparisons test.
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Extended Data Fig. 3 | See next page for caption.
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Extended Data Fig. 3 | Impact of F4/80hi HO-1+ TAMs accumulation at the invasive tumor margin on metastasis formation and tumor angiogenesis. 
a, (top) Representative confocal microscopy of WT MN/MCA1 tumor sections (a-b: peripheral marginal zone; c: inner area). F4/80 (red), HO-1 (green), 
nuclei (DAPI, blue). Representative images are shown, scale bars are 10!&m, n!=!5 mice, one experiment was performed. (bottom) Expression of HO-1 in 
WT MN/MCA1 tumor sections (top: inner area; bottom: periphery). Consecutive sections from the same formalin-fixed paraffin-embedded (FFPE) lesion 
were stained for F4/80 and HO-1. Scale bars are 200!&m, n!=!4 mice, one experiment was performed. b, Expression of HO-1 in the neoplastic tissue of a 
lymph node metastasis from a melanoma patient. The analysis is representative of n!=!5 patients, one experiment was performed. Left panels, Consecutive 
sections from the same FFPE lesion were stained for CD68, CD163 and HO-1. Middle panels, Low magnification images showing cell staining for the three 
markers. Right panels, Higher magnification images of the indicated areas. Two bottom panels, quantitative analysis of the spatial distribution of HO-1+ 
cells by QuPath software (HO-1+ cells: red, HO-1% cells: blue). c, area of metastatic burden quantified from H&E stained lung sections from Hmox1fl/fl and 
Hmox1fl/flLyz2-Cre- bearing mice expressed as a percentage of total lung surface area. Representative images are shown. Scale bars, 1!mm. n!=!6 (Hmox1fl/fl) 
and n!=!7 (Hmox1fl/flLyz2-Cre), one experiment was performed. d, FACS quantification of CD31+ cells in lung metastasis of n!=!6 Hmox1fl/fl and n!=!6 Hmox1fl/
flLyz2-Cre MN/MCA1-bearing mice; one experiment was performed. e (top, left), Representative images of MN/MCA1 tumor sections from Hmox1fl/fl 
and Hmox1fl/flLyz2-Cre mice injected with FITC-Dextran. Sections were co-stained for FITC-Dextran (green) and CD31 (red); (top, right) quantification of 
vascular permeability; (bottom) Representative images of MN/MCA1 tumor sections from Hmox1fl/fl and Hmox1fl/flLyz2-Cre mice co-stained for collagen 
IV (green), CD31 (red) and $-SMA (white) and quantification of vessel stability, n!=!3 mice per genotype, one experiment was performed. f, FACS 
quantification of VEGF, HIF$ in TAMs subsets and VEGFR in CD31+ cells in tumors (top) and lung metastasis (bottom) of Hmox1fl/fl and Hmox1fl/flLyz2-Cre 
MN/MCA1-bearing mice; n!=!5 mice per genotype (tumor), n!=!4 mice per genotype (metastasis), one experiment was performed. Data are mean ± 
SEM. *P!<!0.05 **P!<!0.01 ***P!<!0.001, ****P!<!0.0001 between selected relevant comparisons. In c-d-e(top)-f, two-tailed unpaired Student’s t-test. In e 
(bottom), two-way ANOVA with Sidak’s multiple comparisons test.
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Extended Data Fig. 4 | Impact of HO-1 on tumor growth, EMT and LPS-treated macrophages. a, Expression of EMT-related genes in MN/MCA1 tumor 
cells FACS-sorted from Hmox1fl/fl and Hmox1fl/flLyz2-Cre mice, shown are pooled data from n!=!3 animals per genotype. b, (left) Growth of B16 melanoma 
in Hmox1fl/fl and Hmox1fl/flLyz2-Cre mice; shown are pooled data from n!=!2 independent experiments with n!=!5 Hmox1fl/fl and n!=!4 Hmox1fl/flLyz2-Cre 
animals per group; (right) macroscopic appearances of lung metastasis are shown; n!=!3 mice per genotype. c, Frequency of TNF+ and CD206+ in TAMs 
subsets and CD31+ cells; n!=!5 (Hmox1fl/fl) and n!=!4 (Hmox1fl/flLyz2-Cre) mice. d, Quantification of IFN"+CD8+ T cells and CD8 : Treg ratio in B16 melanoma 
grown in Hmox1fl/fl and Hmox1fl/flLyz2-Cre mice, n!=!6 (Hmox1fl/fl) and n!=!4 (Hmox1fl/flLyz2-Cre) mice. e, Expression of EMT-related genes in B16 tumor cells 
FACS-sorted from Hmox1fl/fl and Hmox1fl/flLyz2-Cre mice; shown are pooled data from n!=!3 animals per genotype. f, WT PECs pre-treated or not with 
ZnPPIX were analyzed by RT-PCR for the expression of representative M1 and M2 cytokine genes; for each condition, cells pooled from n!=!3 mice were 
used. g-h, PECs from WT or p50–/– mice (g) or Hmox1fl/fl and Hmox1fl/flLyz2-Cre mice (h) pre-treated or not with CORM-2 were analyzed by RT-PCR for the 
expression of representative M1 and M2 cytokine genes. Results are given as mRNA fold increase over untreated cells (M/M); for each condition, cells 
pooled from n!=!3 mice were used. i, Frequency of F480+Ly6Clow/negSiglecF% blood monocytes and relative C5aR1, C3aR and HO-1 expression in LPS-treated 
WT and p50–/– mice; n!=!5 (WT: 0h and 6h), n!=!5 (WT: 24h, p50–/–: 0h), n!=!4 (p50–/–: 6h and 24h). Data are mean ± SEM. *P!<!0.05, **P!<!0.01, 
***P!<!0.001, between selected relevant comparisons. In a, d, e, f, g, h, i, two-tailed unpaired Student’s t-test. In b, c, two-way ANOVA with Sidak’s multiple 
comparisons test. The data in b (left), c, d, are representative of two independent experiment; in a, b (right), e, f-i one experiment was performed.
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Extended Data Fig. 5 | Role of p50 NF-!B, CSF1R and C3aR in the generation of HO-1+ myeloid cells. a, FACS quantification of Nrf2 expression by F4/80hi 
and F4/80lo TAMs in WT MN/MCA1 tumors (left), n!=!4 mice; Nrf2 and HO-1 expression by F4/80hi in WT, C3–/–, p50–/– and anti-CSF1R treated MN/
MCA1-bearing mice (middle, right), n!=!4 (WT, p50–/–) and n!=!3 (C3–/–, anti-CSF1R) mice per group. b, CD115 expression of TAMs subsets in WT, C3–/– and 
p50–/– MN/MCA1-bearing mice, n!=!4 (WT, p50–/–) and n!=!3 (C3–/–, anti-CSF1R) mice. c, FACS analysis of Nrf2, HO-1 and CD115 expression in WT and 
p50–/– PECs stimulated or not with C3 (+=variation compared to isotype control), for each condition, cells were pooled from n!=!4 mice. d, FACS analysis 
of Nrf2, HO-1 and C3aR expression in WT, p50–/– and C3–/– PECs stimulated or not with M-CSF, for each condition, cells pooled from n!=!4 mice were used. 
e, FACS analysis of Nrf2 and HO-1 expression in WT and Nfe2l2–/– BM-DMs stimulated or not with M-CSF and C3; for each condition, cells were pooled 
from n!=!4 mice. f, (top) macroscopic lung metastasis quantification in WT, anti-CSF1R, C3–/, p50–/– (left) and in Hmox1fl/fl and Hmox1fl/flLyz2-Cre MN/
MCA1 tumor-bearing mice (right), treated or not with Brusatol. (bottom) area of metastatic burden was quantified in H&E stained lung sections from WT 
MN-MCA1-bearing mice treated with vehicle or Brusatol and is expressed as a percentage of total lung surface area. Representative images are shown. 
Scale bars, 1!mm. g, (top) FACS quantification of F4/80hi and F4/80lo TAMs and relative HO-1 expression levels in WT, anti-CSF1R, C3–/–, p50–/– MN/MCA1 
tumor bearing mice, treated with brusatol; (bottom) percentage of LSK, LK, CMPs, MEPs and GMPs and relative HO-1 expression in the BM of untreated 
and brusatol-treated MN-MCA1-bearing WT mice. Data are mean ± SEM. *P!<!0.05 **P!<!0.01 ***P!<!0.001, between selected relevant comparisons. In 
a one-way ANOVA or two-tailed unpaired Student’s t-test. In b–g, two-way ANOVA with Sidak’s multiple comparisons test. In a-g, one experiment was 
performed.
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Extended Data Fig. 6 | Effects of HO-1 antagonist (ZnPPIX) on immune infiltrate and tumor growth. a, Mean ±- SEM tumor volume of B16 implants 
in WT mice treated with vehicle or ZnPPIX; n!=!5 mice per group. b, FACS quantification of TNF and CD206 expression in F4/80hi and F4/80lo TAMs 
subsets; n!=!6 mice per group. c, Quantification of IFN" expression in B16 tumor-infiltrating CD8+ T lymphocytes and CD8 : Treg ratio in vehicle- and 
ZnPPIX-treated mice; n!=!5 mice per group. d, TAMs purified from MN/MCA1 tumors growing in WT mice treated or not with ZnPPIX were analyzed by 
RT-PCR for the expression of representative M1 and M2 cytokine genes; shown are pooled data from n!=!2 technical replicates from n!=!4 mice. e, FACS 
quantification of HO-1 expression in F4/80hi and F4/80lo TAMs subsets and in MN/MCA1 (left, n!=!5 mice) or B16 tumor cells (right, n!=!3 mice) in WT 
mice. f, (left) Mean ± SEM tumor volume of subcutaneous B16 implants in n!=!5 Hmox1fl/fl and n!=!5 Hmox1fl/flLyz2-Cre treated with vehicle or ZnPPIX; 
(right) proliferation rates of B16 and MN/MCA1 cells in primary tumors and lung metastasis of mice treated with vehicle or ZnPPIX; B16: n!=!5 (vehicle), 
n!=!4 (ZnPPIX); MN/MCA1: n!=!4 (tumor) and n!=!3 (metastasis). g, Representative images of K1735-M2 lung metastasis and quantification of K1735M2 
melanoma cells in C3HN mice treated or not with ZnPPIX; n!=!7 (Vehicle) and n!=!6 (ZnPPIX). h TAMs purified from MN/MCA1 tumors growing in WT 
mice treated or not with CORM-2 were analyzed by FACS for pSTAT1, pSTAT3, pSTAT6 expression (top, n!=!3 mice) and by RT-PCR for the expression of 
representative M1 and M2 cytokine genes (bottom, n!=!4 mice), i, FACS quantification of CD31+ cells, E-cadherin+, N-cadherin+ and Vimentin+ mCherry+ 
MN/MCA1 cells in primary tumors of T lymphocyte-depleted MN-MCA1-bearing WT mice, treated or not with ZnPPIX, n!=!5 (Vehicle and ZnPPIX) 
and n!=!4 (anti-CD4/CD8+ZnPPIX). j, Mean ± SEM tumor volume and size of B16 tumors growing in WT mice treated with Vehicle, anti-PD-1 antibody, 
ZnPPIX, or anti-PD-1 antibody plus ZnPPIX are shown, n!=!2 (Vehicle), n!=!3 (anti-PD-1 and ZnPPIX) and n!=!4 (anti-PD-1+ZnPPIX). Data are mean ± SEM. 
*P!<!0.05 **P!<!0.01 ***P!<!0.001, between selected relevant comparisons. In a, b, f, j, two-way ANOVA with Sidak’s multiple comparisons test. In c, d, f, g, 
h, two-tailed unpaired Student’s t-test or Mann–Whitney U-test. In e, i one-way ANOVA and Kruskal-Wallis test with Dunn’s multiple comparisons test. 
The data in a–c, are representative of two independent experiment; in d–j one experiment was performed.
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Extended Data Fig. 7 | Gating strategy for the assessment of HO-1 in peripheral blood monocyte subsets. a, Monocytes from peripheral blood samples 
were identified as CD45+ CD3% CD19% CD56% cells after doublet exclusion, live cell selection and FS-A vs. SS-A gating (upper set of dot plots). Intracellular 
HO-1 expression (geometric mean fluorescence intensity, gMFI) detected in permeabilized cells was then recorded in 15 monocyte subsets (R1 to R3 
and R1R5 to R3R8) defined by differential expression of CD14, CD16, CD88 and Tie-2. b, Median HO-1 gMFI values for each of the 15 monocyte subsets 
observed in peripheral blood samples from the discovery, confirmation and combined sets (discovery + confirmation). c, Expression of HO-1 (gMFI) in 
main monocyte subsets in peripheral blood samples from the discovery (n!=!47) and confirmation (n!=!45) sets of AJCC stage IIIC and IV melanoma 
patients. Statistical analysis of the combined set (discovery+confirmation cohorts) gMFI HO-1 values by Kruskal Wallis test followed by Dunn’s multiple 
comparisons test. ns= not significant; *: P!<!0.05; **: P!<!0.01; ****: P!<!0.0001.
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Extended Data Fig. 8 | Stratification of melanoma patients’ survival based on the subset-specific median HO-1. a, Schematic of the gating strategy to 
identify twelve monocyte subsets (R1R5 to R3R8) in the peripheral blood of melanoma patients, based on differential expression of CD14, CD16, CD88 and 
Tie-2. b, Kaplan Meyer survival analysis in discovery and confirmation sets stratified by HO-1 gMFI higher or lower than the combined set median value 
observed in each monocyte subset.
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Extended Data Fig. 9 | See next page for caption.
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Extended Data Fig. 9 | Prognostic significance of myeloid-specific HO-1. a, expression of CD163 and HO-1 in metastatic lesions of AJCC Stage III 
melanoma patients. Consecutive sections from lesions (LN=lymph node; s.c.: subcutaneous) of 10 patients were stained for CD163 and HO-1. Wide field 
images and higher magnification insets are shown centered on the same area of the tumor tissue for both markers. Lesions from patients #1 to #8 (short 
survival) show expression of both CD163 and HO-1 in the same areas of the tumor tissue. Lesions from patients #11 to #15 (long survival) show lack of 
both CD163 and HO-1 expression. For each patient, survival was computed from the date of surgery for removal of metastatic lesions. Status: DOD: dead 
of disease, NED: no evidence of disease. b, results of multivariable Cox proportional hazard model on TCGA skin cutaneous melanoma dataset (n!=!471) 
were obtained through the outcome module of TIMER2.0 web server, by testing the relevance of tumor infiltrating macrophages, as identified by the M2_
TIDE macrophage signature52, and of the expression of macrophage-related genes CD163, HO-1 and CD68. Tumor stage was included as clinical covariate.
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